Capitalmind
Capitalmind
Actionable insights on equities, fixed-income, macros and personal finance Start 14-Days Free Trial
Actionable investing insights Get Free Trial

5 ArticlesDIVISLAB

1 / 1

Outlier in Focus – Divi’s Laboratories.

We come across a large number of interesting stocks in Capitalmind SNAP Outliers, our discovery tool for stocks with momentum. Here’s a look at Divi's ...
Outlier-in-Focus.png

Earnings Report: 3QFY17 : 495 Companies Till Now With Management Comments

Here is a quick summary of the third quarter financial results for all the companies announced till date. For some companies, management comments have been ...
Sectoral-10022017.png

We Reveal The Form 483 Issued By US FDAs Inspection Of Divis Laboratories Unit-II At Visakhapatnam

Here is our coverage of the Form 483 issued by the US FDA from the inspection of Divis Laboratories Unit-II located at Visakhapatnam. You can catch all our ...
Divis-Laboratories-FDA-Inspection.png

Alkem Laboratories & Divis Laboratories Receive Form 483 From US FDA

With the dust yet to settle on the US FDAs inspection of Sun Pharmaceuticals Mohali, Punjab and Halol, Gujarat plants, 2 more companies have reported receiving ...
Alkem-Manufacturing-Plants.png

FDA’s New Rules Propels Generic and Biosimilar Approvals

Effective January 9th 2017, the US Food and Drug Administration (FDA) has announced an amendment to the final rule ((the rule governs the manner in which FDA ...
Original-Abbreviated-New-Drug-Application-ANDA-Approvals-10-November-2016.png